The findings demonstrate that both compounds selectively and potently inhibit BChE, with minimal activity against AChE, suggesting a promising therapeutic profile for AD patients, in whom BChE becomes the predominant cholinesterase in the brain. The gene discussed is ACHE; the disease is Alzheimer disease.